| Name | Title | Contact Details |
|---|
G-CON Manufacturing, Inc.`s prefabricated, turnkey cleanroom systems represent a significant transition to forward thinking in pharmaceutical and biopharmaceutical processing. G-CON Manufacturing, the innovator of autonomous cleanroom PODs, turned the challenges experienced by the biopharmaceutical industry into readily deployable, flexible, mobile and scalable cleanroom solutions. PODs are ideal for multi-product sites, rigorous containment needs, and on demand scaling of production and laboratory space. Building on its first design in 2009, G-CON now has a wide array of cleanroom PODs in their product portfolio to accommodate the increased demand from the pharmaceutical, biopharmaceutical and cell therapeutic industries. Moreover, G-CON`s patent portfolio continues to grow which will effectively preclude imitators from copying G-CON`s initial and more recent innovations. At G-CON, we will continue to evolve and grow with the industry to provide a comprehensive cleanroom solution that truly is flexible, scalable and fast, all for a fair and known price from the time the contract is signed.
Spine Team Texas is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Integrated Biomolecule Corporation is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmaron is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. -We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses. -We are creating a new biopharmaceutical category for autoimmunity. We leverage a transformational drug development strategy that sources, repositions and advances candidates that: -Target the interception or prevention of immune-mediated disease -Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons -Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.